8 hrs Safety Evaluation Of A Multi-Pressure Dial In Eyes With Glaucoma: Prospective, Open-Label, Randomized Study.

To investigate the safety and tolerability of the multi-pressure dial with a continuous 8-hr duration in subjects with open-angle glaucoma. Prospective, controlled open-label, randomized, single site study. Twenty eyes of 10 subjects with open-angle glaucoma were fitted with a multi-pressure dial and randomized to negative pressure application of -10 mmHg in one eye for 8 (continuous) hours and ambient atmospheric pressure in the contralateral eye. Main safety outcome measures include best-corrected visual acuity (BCVA), intraocular pressure (IOP) changes from baseline after negative pressure application, slit lamp and dilated fundus exam findings, and rate of adverse events. Subjective assessments were administered both hourly during the 8-hr study period and immediately following the study period. There were no statistically significant changes in IOP, BCVA or TBUT immediately following the 8-hr study period or at the 1-week follow-up visit. Patient-reported tolerability was favorable with a mean response of 1.8 ± 0.4 (scale → 1=best, 10 = worst). Subjects also reported positive interest in the MPD as a glaucoma therapy with a mean response of 1.8 ± 0.5 (scale → 1=best, 10 = worst). One adverse event was reported (headache) and resolved at conclusion of the Day 0 visit. The MPD demonstrated favorable safety with key parameters remaining stable after an 8-hr wear with negative pressure. Negative pressure application through the MPD was well tolerated by subjects enrolled in the study. The favorable findings demonstrate the safety of sustained delivery of negative pressure over a continuous, uninterrupted 8-hr duration.

Informations de copyright

© 2019 Samuelson et al.

Déclaration de conflit d'intérêts

Dr. Berdahl is the founder and CEO of Equinox Ophthalmic, Inc. Dr Berdahl reports personal fees from Alcon, Aurea Medical, Bausch and Lomb, Equinox, Glaukos, Gore, Johnson and Johnson, Kala, Kedalion, MicroOptx, New World Medical, Orasis, Oyster Point, Surface INC, Tarsus, ViaLase, Vittamed, Vance Thompson Vision, Verana Health, Visionary Ventures, and Zeiss, during the conduct of the study; personal fees from Allergan, Avedro, CorneaGen, Dakota Lions Eye Bank, Expert Opinion, Imprimis, MELT Pharmaceuticals, Ocular Surgical Data, Ocular Theraputix, Omega Ophthalmic, RxSight, Surface, INC, Tear Clear, outside the submitted work. Drs. Samuelson, Ferguson, Radcliffe, Schweitzer and Swan are consultants for Equinox Ophthalmic, Inc. Dr Lewis reports personal fees from Aerie, during the conduct of the study; personal fees from Aerie, Alcon, Allergan, Glaukos, Ivantis, MicroOptx, Zeiss, and AVS, outside the submitted work. The authors report no other conflicts of interest in this work.